Thiel-backed Lindus Therapeutics sells CRO division and shifts focus to acquiring drug assets
Lindus Therapeutics, a transatlantic startup backed by Peter Thiel, announced the sale of its contract research organization (CRO) arm.
The company, previously positioning itself as an “anti‑CRO,” will use the proceeds to transition from operating clinical trials to seeking external drug assets for development.
By focusing on drug acquisition rather than trial services, Lindus aims to leverage its experience in trial execution to build a pipeline of promising candidates.
The move reflects a broader trend of biotech firms re‑evaluating business models amid a competitive development landscape.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Thiel-backed Lindus sells CRO arm in pivot to hunt for drug assets”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that